Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
Greaves
Mike
M
Department of Medicine Therapeutics, University of Aberdeen, Foresterhill, Scotland, Great Britain. m.greaves@abdn.ac.uk
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use*; D001780:Blood Coagulation Tests / Q000592:standards*; D002648:Child; D065427:Factor Xa Inhibitors; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006493:Heparin / Q000009:adverse effects / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D011247:Pregnancy; D011516:Prothrombin / Q000037:antagonists & inhibitors; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D011516:Prothrombin; D006493:Heparin